CAS Number: 54739-18-3
It is excreted into breast milk in non-significant amount. Plasma level in infants from mother who receive Fluvoxamine is usually undetectable. Not effects on the infant's physical and psychomotor development at both short or long-term were found. Because there is less experience published than with other antidepressants of the same pharmacological group, it should be preferred the use of an alternative drug that is known to be safer in the neonatal period or prematurity. Galactorrhea has been observed but less frequently than with other antidepressants. In cases of treatment with xanthines (theophylline, caffeine) for apnea of prematurity, the plasma level of them should be monitored because Fluvoxamine is a strong inhibitor of activity of the Cytochrome P450-CYP1A2 which is responsible for metabolic elimination of xanthines. Women who use antidepressant medication during pregnancy are in need of more support for breastfeeding since they are at risk for early weaning.
CAS Number: 54739-18-3
Limited information indicates that maternal fluvoxamine doses of up to 300 mg daily produce low levels in breastmilk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months. One infant was reported to have an elevated serum level of fluvoxamine, but most who have been tested have undetectable serum levels. Another infant developed diarrhea, vomiting and stimulation after maternal initiation of fluvoxamine. A limited amount of long-term follow-up on growth and development has found no adverse effects in breastfed infants. Mothers taking an SSRI during pregnancy and postpartum may have more difficulty breastfeeding, although this might be a reflection of their disease state. These mothers may need additional breastfeeding support. Breastfed infants exposed to an SSRI during the third trimester of pregnancy have a lower risk of poor neonatal adaptation than formula-fed infants.
It is always a good idea to keep your healthcare provider or doctor informed about your drug usage during pregnancy and breastfeeding but if you have not informed your doctor about Fluvoxamine Maleate 1 In 1 Pouch and have used it then do not panic as Fluvoxamine Maleate 1 In 1 Pouch is mostly safe in breastfeeding and should not cause any harm to your baby.
Definitely, Fluvoxamine Maleate 1 In 1 Pouch is safe in lactation for baby. No wonder your doctor has recommended it.
No extra baby monitoring required while mother is using Fluvoxamine Maleate 1 In 1 Pouch
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week